Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant angiopoietin-like 4
- Development stage
- Preclinical
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant angiopoietin-like 4 (rhANGPTL4) is a recombinant version of the endogenous ANGPTL4 protein, a member of the angiopoietin-like family. It acts as a potent modulator of lipid metabolism by functioning as a non-competitive inhibitor of lipoprotein lipase (LPL), thereby regulating the hydrolysis of triglyceride-rich lipoproteins. Beyond its metabolic role, rhANGPTL4 has demonstrated protective effects on vascular and mucosal barriers, specifically protecting the blood-brain barrier and the intestinal lining. In preclinical models, it has shown therapeutic potential in treating intestinal ischemia/reperfusion injury, reducing proteinuria in glomerular diseases, and mitigating inflammation in inflammatory bowel diseases (IBD) such as Crohn's disease and ulcerative colitis by downregulating CD8+ T cell and macrophage activity.
- Other names
- recombinant human angiopoietin-like protein 4recombinant ANGPTL4recombinant angiopoietin-related protein 4
02
Targets
ITGB1 (Integrin beta-1)ITGB5 (Integrin beta-5)LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on recombinant angiopoietin-like 4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant angiopoietin-like 4.